Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Hits Expectations

Shattuck Labs (NASDAQ:STTK) announced its quarterly earnings results on Thursday. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12), FiscalAI reports. The firm had revenue of ($1.00) million for the quarter.

Shattuck Labs Trading Up 7.8%

Shares of STTK stock opened at $5.10 on Friday. The company has a market capitalization of $322.73 million, a price-to-earnings ratio of -5.00 and a beta of 1.55. The firm has a 50-day moving average price of $4.12 and a 200 day moving average price of $2.79. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $5.20.

Hedge Funds Weigh In On Shattuck Labs

A number of institutional investors have recently modified their holdings of the company. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Shattuck Labs during the 3rd quarter worth $29,000. Virtu Financial LLC acquired a new position in shares of Shattuck Labs during the 3rd quarter valued at about $38,000. AQR Capital Management LLC lifted its holdings in shares of Shattuck Labs by 265.4% during the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after acquiring an additional 31,355 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Shattuck Labs in the second quarter worth approximately $44,000. Finally, Squarepoint Ops LLC purchased a new stake in Shattuck Labs in the third quarter valued at approximately $46,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on STTK shares. HC Wainwright raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a report on Monday, December 1st. Wedbush lifted their price target on Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research note on Friday. Piper Sandler began coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. Finally, Citigroup lifted their target price on shares of Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.